For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system. Published in Cancer, November 2013.
By Hagop Kantarjian, M.D., Department of Leukemia, The University of Texas MD Anderson Cancer Center; and Leonard Zwelling, M.D., Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
Aug. 26, 2013, 4:05 p.m.